RGNX REGENXBIO Inc.

$8.53▼ -0.35% Healthcare Other
After hours $8.47▼ -0.70% Sep 11, 7:30 PM ET
Volume 1.03M Avg Volume (10D) 1.15M
Key Metrics & Fundamentals
Market Cap
$563.09M
P/E Ratio
–
Div Yield
–%
52W Range
5.46 - 16.19
% vs 50 MA
-20.25%
% vs 200 MA
-16.99%
RSI-14
38.6
MACD Histogram
-0.1000
Beta (1Y vs SPY)
2.01
Free Cash Flow
-$63.00M
Gross Rev
$108.02M
Gross Profit
$106.98M
EBITDA
$33.04M
COGS
$1.04M
Operating Exp
$77.71M
Operating Income
$29.26M
EBIT
$29.26M
Pretax Income
$22.71M
Net Income
$22.71M
EPS (Diluted)
0.43
Price & Volume History
Loading chart…
Recent News
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire · Sep 8, 2026 11:05 AM
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Insider Monkey · Sep 5, 2026 12:23 AM
Top Premarket Gainers
MT Newswires · Aug 28, 2026 11:15 AM
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
PR Newswire · Aug 25, 2026 11:05 AM
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Stocktwits · Aug 25, 2026 10:50 AM
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Hospital Management · Aug 25, 2026 10:21 AM
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Aug 24, 2026 7:47 PM
RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy
Stocktwits · Aug 24, 2026 7:18 PM
Top Midday Decliners
MT Newswires · Aug 24, 2026 6:10 PM
Sector Update: Healthcare Stocks Decline in Afternoon Trading
MT Newswires · Aug 24, 2026 5:50 PM
Financial Overview - Income Statement Quarterly

See RGNX's money flow as a full page

Social Sentiment
Avg +0.75 · 2 posts
DiscussionFavorite mid-cap biotech with the most upside? (500M–2.5B mkt cap)
r/investing · Dec 22, 2025
Mentioned as a potential investment, and a point of discussion.
positive +0.70
Ripe for picking - (FDMT) 4D Molecular Therapeutics?
r/stocks · Oct 20, 2024
The post presents a highly optimistic financial model and potential for RGNX, driven by the promising 4D-150 drug candidate.
positive +0.80
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙